93 reports

  • BREAST CANCER LIQUID BIOPSY MARKET BY CIRCULATING BIOMARKERS (CAGR 2017 - 2022)
  • BREAST CANCER LIQUID BIOPSY MARKET, BY CIRCULATING BIOMARKER, 2015-2022 (USD MILLION)

(US) ctDNA and exosome RNA Fluxion Biosciences, Inc.

  • Breast Cancer
  • United States
  • Market Size
  • Biocept, Inc.
  • Biodesix Inc.

Gland Surgery; ##(##): ##-## Zhang P, et al. (2016).

  • Breast Cancer
  • Cancer
  • AstraZeneca PLC
  • Novartis AG
  • Roche Group

ipage=##& xml=##& quest=##& rid=##& section=##& sequence=-##& pdf=##& dn=## [Accessed February ##, 2017].

  • Breast Cancer
  • Company
  • Novartis AG
  • Pfizer Inc.
  • Roche Group
  • Breast Cancer Therapeutics Market, Global, All Pipeline Products, Phase II, 2016
  • 9 Appendix

Subjects were randomized in a ##:##:## ratio to receive no additional treatment, one year of Herceptin treatment or two years of Herceptin treatment.

  • Breast Cancer
  • Market Size
  • AstraZeneca PLC
  • Genentech, Inc.
  • Novartis AG
  • RNA DISRUPTION ASSAY - BREAST CANCER
  • Rna Diagnostics Inc Pipeline Products Overview

Rna Diagnostics is one of three businesses selected to participate in this pilot program.

  • Breast Cancer
  • Diagnostics
  • RNA
  • Canada
  • Company

Advancement in current technologies is such that one can now examine ribonucleic acid (RNA), deoxyribonucleic acid (DNA), and protein directly from the patient' s own tumor.

  • Breast Cancer
  • HPV Testing
  • China
  • East Asia
  • OriGene Technologies, Inc.

Cancers that produced a small molecule of RNA called MIR## seemed able to resist treatment more than those with low levels.

  • Breast Cancer
  • United Kingdom
  • Cancer Research Technology Limited
  • Merck & Co., Inc.
  • Merck Serono S.A.

The Aptima HIV-## Quant assay is a nucleic acid amplification test for the quantitative detection of RNA from HIV in plasma specimens.

  • Breast Cancer
  • World
  • Business Expansion & Exit
  • Demand
  • Hologic, Inc.

Measuring P##K activation: clinicopathologic, immunohistochemical, and RNA expression analysis in prostate cancer.

  • Breast Cancer
  • Market Size
  • Novartis AG
  • Pfizer Inc.
  • Roche Group

This, in turn, inhibits the normal DNA and RNA synthesis required for cell growth.

  • Breast Cancer
  • World
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.

One million blood cells are scanned in just one minute.

  • Breast Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

One million blood cells are scanned in just one minute.

  • Breast Cancer
  • United States
  • Market Size
  • Illumina, Inc.
  • Trovagene, Inc.

PLoS One; ##: ##-## Siddiqui M and Perry CM (2012).

  • Breast Cancer
  • Market Size
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Merck & Co., Inc.

ua: ##.

  • Breast Cancer
  • Market Size
  • Genentech, Inc.
  • Novartis AG
  • Pfizer Inc.
  • 5.3.1 United States - Liquid Biopsy Colorectal Cancer Potential Market
  • United States - Liquid Biopsy Colorectal Cancer Potential Market (Million US$), 2015 - 2020

These include proteins, RNA and DNA.

  • Breast Cancer
  • North America
  • United States
  • Forecast
  • Biocept, Inc.
  • 20.1 COMPETITIVE SCENARIO

These metabolites act by inhibiting thymidylate synthase, which interferes with DNA synthesis and RNA synthesis.

  • Breast Cancer
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Hoffmann-La Roche Inc.
  • Parsortix-Based Test - Breast Cancer - Product Description
  • ANGLE PLC, RECENT DEVELOPMENTS

It is performed using Parsortix system to evaluate RNA from the cell harvests.

  • Breast Cancer
  • Cancer
  • United States
  • World
  • Product Initiative

Fluorouracil is converted to the active metabolite ##-fluoroxyuridine monophosphate (F-UMP) which replaces uracil incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth.

  • Breast Cancer
  • Cancer
  • United States
  • Product Initiative
  • Pfizer Inc.

Cyclin-dependent kinases (CDKs) are critical regulators of cell cycle progression and RNA transcription.

  • Breast Cancer
  • United States
  • World
  • Product Initiative
  • Pfizer Inc.

In addition, this agent appears to interfere with CDK-mediated phosphorylation of the carboxy-terminal domain of RNA polymerase II, inhibiting RNA polymerase IIdependent transcription, which may result in the down-regulation of antiapoptotic proteins such as induced myeloid leukemi

  • Breast Cancer
  • Therapy
  • United States
  • Product Initiative
  • Syros Pharmaceuticals, Inc.

Cyclin-dependent kinases (CDKs) are critical regulators of cell cycle progression and RNA transcription.

  • Breast Cancer
  • United States
  • World
  • Product Initiative
  • Pfizer Inc.

Sparano, M. D., Montefiore Medical Center Plenary Session Time: ##:## p. m.

  • Breast Cancer
  • Chemotherapy
  • Genomics
  • Prostate Cancer
  • Genomic Health, Inc.

GO-2032c is a mucin ## (MUC-##) protein inhibitor.

  • Breast Cancer
  • Cancer
  • Vaccine
  • United States
  • Product Initiative
  • 18.1 COMPETITIVE SCENARIO

These agents substitute the building blocks of DNA and RNA during the S phase of the cell cycle, inhibiting normal DNA and RNA synthesis.

  • Breast Cancer
  • United States
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc

Antiviral responses in HCV- and HBV-infected patients have been observed as measured by declines in HCV RNA and quantitative HBV surface antigen.

  • Breast Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

Location: Hall A Time: ##:## - ##:## p. m.

  • Breast Cancer
  • Cancer
  • Genomics
  • Company Financials
  • Genomic Health, Inc.
  • MAY 18, 2017: PHARMAMAR ANNOUNCES NEW DATA ON LURBINECTEDIN DURING ASCO 2017
  • JUN 13, 2017: PHARMAMAR ANNOUNCES ENCOURAGING RESULTS IN CLINICAL TRIALS OF LURBINECTEDIN IN ENDOMETRIAL AND BREAST CANCERS

It is an inhibitor of RNA polymerase II.

  • Breast Cancer
  • Medical Biotechnology
  • United States
  • Company
  • Pharma Mar, S.A.

Fluorouracil is converted to the active metabolite ##-fluoroxyuridine monophosphate (F-UMP) which replaces uracil incorporates into RNA and inhibits RNA processing, thereby inhibiting cell growth.

  • Breast Cancer
  • Chemotherapy
  • Targeted Therapy
  • Therapy
  • Pfizer Inc.

One unit refers to one Biopsy Forceps.

  • Biopsy
  • Breast Cancer
  • Medical Device
  • United States
  • Verisante Technology, Inc.
  • R&D Progress Research and Development Brief

The study enrolled ## patients who were randomized ##:## to one of two treatment groups: one which will receive Pexa-Vec followed by sorafenib and one which will receive sorafenib alone.

  • Breast Cancer
  • Cancer
  • United States
  • World
  • Product Initiative